Advanced search×

Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

Anticancer Res 30(10):4317-23 (2010) PMID 21036758

There is currently no standard of treatment for patients with hormone refractory prostate cancer (HRPC) after failure of docetaxel-based chemotherapy. The purpose of this study was to assess the anticancer activity and tolerance of metronomic cyclophosphamide prednisolone combination in this setting.

Version: za2963e q8za5 q8zb8 q8zc4 q8zdd q8zed q8zfb q8zg2

Similar articles you may find interesting…

  1. Children's Oncology Group's 2013 blueprint for research: Bone tumors

    Pediatr Blood Cancer 60(6):1009-1015 (2013) PMID 23255238

    In the US, approximately 650 children are diagnosed with osteosarcoma and Ewing sarcoma (ES) each year. Five-year survival ranges from 65% to 75% for localized disease and <30% for patients with metastases. Recent findings include interval-compressed five drug chemotherapy improves s...
  2. Pediatric lupus nephritis: more options, more chances?

    Lupus (2013) PMID 23629826

    Lupus nephritis (LN) is more common and severe in childhood-onset systemic lupus erythematosus (SLE) than in adults. It is one of the major causes of acute kidney injury (AKI) and chronic kidney disease (CKD) in children. Steroid therapy has been used as the first-line treatment for...
  3. Has the time come for metronomics in low-income and middle-income countries?

    Lancet Oncol 14(6):e239-48 (2013) PMID 23639324

    We will briefly review the rationale behind the combination of metronomic chemotherapy and drug repositioning-an approach we term metronomics. We assess the clinical experience obtained with this kind of anticancer treatment and describe potential new developments in countries with limited resources...